Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
28 Marzo 2024 - 6:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a
commercial-stage, patient-centric biopharmaceutical company focused
on in-licensing, developing, and commercializing novel high-quality
medicines for patients living with rare and difficult-to-treat
diseases, today announced its endorsement of the inaugural
Lambert-Eaton myasthenic syndrome ("LEMS") Awareness Day. This
landmark event, now officially observed annually on March 30th,
signifies a meaningful milestone for the LEMS community. The chosen
date holds profound historical significance, coinciding with the
publication of Dr. Edward Lambert and Dr. Lee Eaton's pioneering
research on LEMS, which has greatly advanced the understanding and
treatment of this rare neuromuscular disorder.
"Creating an awareness day for LEMS is a huge
win for our community," said Price Wooldridge, Founder and Board
Member of the LEMS Family Association. "This brings us one step
closer to our goal, improving the awareness of our rare condition
in the larger population. We couldn't be more thrilled to celebrate
the milestone of this first LEMS Awareness Day together."
"In the realm of rare diseases, awareness is the
key that unlocks paths to diagnosis and treatment. By shedding
light on LEMS, we pave the way for better support, understanding,
and care for those who need it most," stated Richard J. Daly, CEO
of Catalyst. "At Catalyst, we are proud to stand alongside the LEMS
Family Association in honoring this pivotal event. Together, we
forge pathways of support and understanding for those affected by
rare diseases, illuminating a brighter future for all."
LEMS is a rare neuromuscular disease that
affects at least 3,600 and potentially up to 5,400 LEMS patients in
the United States. For more information, please visit
www.lemsfamily.org and www.lemsaware.com.
About Catalyst Pharmaceuticals,
Inc.With exceptional patient focus, Catalyst is committed
to developing and commercializing innovative first-in-class
medicines that address rare and difficult-to-treat diseases.
Catalyst's flagship U.S. commercial product is
FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the
treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for adults
and for children ages six to seventeen. In January 2023,
Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. On July 18th, 2023, Catalyst
acquired an exclusive license for North America for
AGAMREE® (vamorolone) oral suspension 40 mg/mL, a novel
corticosteroid treatment for Duchenne Muscular Dystrophy. AGAMREE
previously received FDA Orphan Drug and Fast Track designations and
was approved by the FDA for commercialization in
the U.S. on October 26th, 2023. AGAMREE became
available in the U.S. by prescription on March 13th, 2024.
For more information about Catalyst
Pharmaceuticals, Inc., visit the Company's website
at www.catalystpharma.com. For Full Prescribing
and Safety Information for FIRDAPSE®,
visit www.firdapse.com. For Full Prescribing
Information, including Boxed WARNING for FYCOMPA®, please
visit www.fycompa.com. For Full Prescribing
Information for AGAMREE®, please
visit https://www.agamree.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and
uncertainties, which may cause Catalyst's actual results in future
periods to differ materially from forecasted results. A number of
factors, including those factors described in Catalyst's Annual
Report on Form 10-K for the fiscal year 2023 and its other filings
with the U.S. Securities and Exchange Commission ("SEC"),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Relations Contact:
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact:
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024